Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Severn Trent reiterates outlook after 'strong' start

(Sharecast News) - Water and sewage firm Severn Trent reiterated its full-year outlook on Thursday, boosted by ongoing work to find and fix leaks. In a trading update, the utility - which supplies around 4.6m homes and business in the Midlands and Wales - said it had seen a "strong start" to the current five-year regulatory period, which runs until 31 March 2030.

As a result, its financial performance for the 2026 full year was on track to meet guidance, with "at least" £25m in outcome delivery incentives reward.

Severn continued: "We anticipate the main contributors of our operational outperformance to be improvements in leakage, driven by increased proactive work to find and fix leaks, and continued efforts to bring down storm overflow spills."

The Coventry-based firm invested around £360m in its capital programme during the first quarter, up 19% year-on-year, while the average sewage spills performance was around five in the first six months of 2025, down 65% on the same period in 2024.

The blue chip is due to publish interim numbers in November. Earlier this week it warned customers that a hose pipe ban remained an option, after a dry spring and hot June meant there was less water than normal in its reservoirs and in rivers.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.